Clinical Trial Update: A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder [Phase 3]

View source ↗

Summary

Phase 3 study of rapastinel as adjunctive therapy to prevent relapse in adults with major depressive disorder has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Rapastinel (Rapastinel)

Snippet

Sponsor: Naurex, Inc, an affiliate of Allergan plc | Conditions: Depressive Disorder, Major | Phase 3 | Status: COMPLETED | Results posted: 2020-03-09